title: Cathepsins and pancreatic cancer: the 2012 update.
abstract: Pancreatic cancer is the result of distinctive genetic and epigenetic disturbances. This multistep process is in part well-defined and includes alterations in oncogenes and suppressor genes that control proliferation, apoptosis, angiogenesis, invasion and cell migration. Cathepsins are proteolytic enzymes and represent potential therapeutic targets in human tumors. Cathepsins predominantly function as endopeptidases within endolysosomal vesicles of normal cells and they are involved in physiological processes such as protein turnover, differentiation and apoptosis. In various types of malignancies, cathepsins have been associated with tumor progression and metastasis. Growing evidence and direct proofs suggest that cathepsins are highly up-regulated in pancreatic cancer and contribute to the development and progression of the cancer phenotype. In this review, the role of cathepsins in pancreatic cancer tumorigenesis is reported and discussed. Some critical aspects will be underlined such as specificity of cathepsin activity in pancreatic cancer and in its precursor lesions; the genetic perturbation and the intracellular signaling pathway activated by cathepsins as reported in preclinical models and in human tissues; the preliminary results and the oncological effects of cathepsin inhibitors currently tested on pancreatic cancer cells; the role of combined therapy based on chemotherapeutic agents and cathepsin inhibition. Although mounting evidences indicate that cysteine cathepsins are potential therapeutic targets in pancreatic cancer, as suggested by their functional role in controlling invasiveness and metastasis, it remains to be seen whether the promising benefits of pharmacological inhibitors observed in preclinical study might be translated to the current clinical practice.
authors.affiliation: Department of Science and Biomedical Technologies, University of L'Aquila, L'Aquila, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Sulpizio
authors.forename: Nicola
authors.initials: N
authors.lastname: Franceschini
authors.forename: Adriano
authors.initials: A
authors.lastname: Piattelli
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Di Sebastiano
authors.forename: Paolo
authors.initials: P
authors.lastname: Innocenti
authors.forename: Federico
authors.initials: F
authors.lastname: Selvaggi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002403:Cathepsins / Q000378:metabolism / Q000502:physiology*; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000209:etiology*; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D015853:Cysteine Proteinase Inhibitors; D002403:Cathepsins